Oncotelic launches new OT-101 corporate presentation; JV re-IPO funding on track

Oncotelic Therapeutics, Inc.

New corporate presentation deployed Feb 7, 2022, covering OT-101 therapeutic programs.
OT-101 program on track to be fully funded by JV for re-IPO, per filing.
No financial figures or milestones disclosed in the 8-K or attached exhibit.
Presentation attached as Exhibit 99.1 but content not available for review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.